# Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

Study · id `cardio:ct-nct02661451` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02661451](<https://clinicaltrials.gov/study/NCT02661451>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02661451

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 178 participants.

## Technical summary

Registry record NCT02661451. Randomized; no masking; primary purpose treatment. Start 2016-09 (actual); primary completion 2023-02-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 178 participants (enrolled count; ClinicalTrials.gov record NCT02661451, source copy `cardio:ctgov-nct02661451-2024-11-27`, retrieved 2026-10-26)
- Started: 2016-09 (actual) (ClinicalTrials.gov record NCT02661451, source copy `cardio:ctgov-nct02661451-2024-11-27`, retrieved 2026-10-26)
- Primary completion: 2023-02-28 (actual) (ClinicalTrials.gov record NCT02661451, source copy `cardio:ctgov-nct02661451-2024-11-27`, retrieved 2026-10-26)
- Completion: 2025-02 (anticipated) (ClinicalTrials.gov record NCT02661451, source copy `cardio:ctgov-nct02661451-2024-11-27`, retrieved 2026-10-26)
- Countries: United States; Canada; Netherlands (ClinicalTrials.gov record NCT02661451, source copy `cardio:ctgov-nct02661451-2024-11-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02661451-2024-11-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)
- Condition: Aortic Valve Stenosis
- Intervention (Device): SAPIEN 3 THV
- Intervention (Biological): Optimal Heart Failure Therapy
- Lead sponsor: Cardiovascular Research Foundation, New York
- Lead sponsor class: OTHER
- Collaborator: Cardialysis BV
- Collaborator class: INDUSTRY
- Collaborator: Avania
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record: SAPIEN 3 transcatheter heart valve (`cardio:sapien-3`)
- Registry lists this organization as the lead sponsor: Cardiovascular Research Foundation, New York (`cardio:org-cardiovascular-research-foundation-new-york`)
- Registry lists this organization as a collaborator: Cardialysis BV (`cardio:org-cardialysis-bv`)
- Registry lists this organization as a collaborator: Avania (`cardio:org-avania`)

## Provenance

Content hash: 774f4d31a49a2fcca419e96be6d950df346526b406e7806561b3d9aceeecf029
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
